High levels of EZH2 in tissue from HCC patients are associated with tumor aggressiveness and poor prognosis [12], and previous studies suggested that EZH2 accumulation is a potential cause of acquired resistance to chemotherapy and immunotherapy [13–17]. The gene discussed is EZH2; the disease is neoplasm.